FDA WARNING_LETTER - Homeolab Inc.

On September 19, 2013, the FDA issued a Warning Letter to Homeolab USA Inc. regarding their drug product, "Kids Relief Earache." The FDA reviewed the product's labeling and marketing information and found it in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act), specifically sections 502, 503, and 301.

The product is deemed a drug under section 201(g)(1)(B) and (C) due to claims like "Relieve mild to severe ear pain," "Soothe throbbing pain & pressure," and "Reduce Inflammation," indicating its intended use for disease treatment or affecting body functions.

Despite being marketed as an OTC drug, "Kids Relief Earache" is classified as a prescription drug under section 503(b)(1) because ear pain requires diagnosis and treatment by a physician, not being a recognized OTC indication. Consequently, the product is misbranded under section 503(b)(4) for failing to bear the "Rx only" symbol.

Furthermore, it is misbranded under section 502(f)(1) for lacking adequate directions for use, as OTC labeling is inappropriate for conditions requiring professional supervision. The product is also misbranded under section 502(a) because its labeling is false or misleading, encouraging OTC treatment for a condition not suitable for self-treatment and